Li, F., & Dong, X. (2021). Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial. Wiley.
Cita Chicago Style (17a ed.)Li, Fengtan, y Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
Cita MLA (8a ed.)Li, Fengtan, y Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
Precaución: Estas citas no son 100% exactas.